Evidence map›Paper›PMID 28800629›Full record

ArticlePloS one2017

Protective effects on the retina after ranibizumab treatment in an ischemia model.

Stephanie C Joachim, Marina Renner, Jacqueline Reinhard, Carsten Theiss, Caroline May, Stephanie Lohmann, Sabrina Reinehr, Gesa Stute, Andreas Faissner, Katrin Marcus and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Synthesis, Characterization, andFrontiers in pharmacology · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. [Marginal protection of retinal cells by bisperoxovanadium : Appropriate therapy in the model of retinal ischemia?]Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Stephanie C JoachimExperimental Eye Research, University Eye Hospital, Ruhr-University Bochum, In der Schornau 23-25, Bochum, Germany.ORCID http://orcid.org/0000-0001-7056-0829
Marina RennerExperimental Eye Research, University Eye Hospital, Ruhr-University Bochum, In der Schornau 23-25, Bochum, Germany.
Jacqueline ReinhardDepartment of Cell Morphology and Molecular Neurobiology, Faculty of Biology and Biotechnology, Ruhr-University Bochum, Universitätsstrasse 150, Bochum, Germany.
Carsten TheissDepartment of Cytology, Faculty of Medicine, Ruhr-University Bochum, Universitätsstrasse 150, Bochum, Germany.
Caroline MayMedizinisches Proteom-Center, Ruhr-University Bochum, Universitätsstrasse 150, Bochum, Germany.
Stephanie LohmannExperimental Eye Research, University Eye Hospital, Ruhr-University Bochum, In der Schornau 23-25, Bochum, Germany.
Sabrina ReinehrExperimental Eye Research, University Eye Hospital, Ruhr-University Bochum, In der Schornau 23-25, Bochum, Germany.
Gesa StuteExperimental Eye Research, University Eye Hospital, Ruhr-University Bochum, In der Schornau 23-25, Bochum, Germany.
Andreas FaissnerDepartment of Cell Morphology and Molecular Neurobiology, Faculty of Biology and Biotechnology, Ruhr-University Bochum, Universitätsstrasse 150, Bochum, Germany.
Katrin MarcusMedizinisches Proteom-Center, Ruhr-University Bochum, Universitätsstrasse 150, Bochum, Germany.
H Burkhard DickExperimental Eye Research, University Eye Hospital, Ruhr-University Bochum, In der Schornau 23-25, Bochum, Germany.
University Hospitals of the Ruhr-University of Bochum · DERuhr University Bochum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Retinal ischemia is common in eye disorders, like diabetic retinopathy or retinal vascular occlusion. The goal of this study was to evaluate the potential protective effects of an intravitreally injected vascular endothelial growth factor (VEGF) inhibitor (ranibizumab) on retinal cells in an ischemia animal model via immunohistochemistry (IF) and quantitative real-time PCR (PCR). A positive binding of ranibizumab to rat VEGF-A was confirmed via dot blot. One eye underwent ischemia and a subgroup received ranibizumab. A significant VEGF increase was detected in aqueous humor of ischemic eyes (p = 0.032), whereas VEGF levels were low in ranibizumab eyes (p = 0.99). Ischemic retinas showed a significantly lower retinal ganglion cell number (RGC; IF Brn-3a: p<0.001, IF RBPMS: p<0.001; PCR: p = 0.002). The ranibizumab group displayed fewer RGCs (IF Brn-3a: 0.3, IF RBPMS: p<0.001; PCR: p = 0.007), but more than the ischemia group (IF Brn-3a: p = 0.04, IF RBPMS: p = 0.03). Photoreceptor area was decreased after ischemia (IF: p = 0.049; PCR: p = 0.511), while the ranibizumab group (IF: p = 0.947; PCR: p = 0.122) was comparable to controls. In the ischemia (p<0.001) and ranibizumab group (p<0.001) a decrease of ChAT+ amacrine cells was found, which was less prominent in the ranibizumab group. VEGF-receptor 2 (VEGF-R2; IF: p<0.001; PCR: p = 0.021) and macroglia (GFAP; IF: p<0.001; PCR: p<0.001) activation was present in ischemic retinas. The activation was weaker in ranibizumab retinas (VEGF-R2: IF: p = 0.1; PCR: p = 0.03; GFAP: IF: p = 0.1; PCR: p = 0.015). An increase in the number of total (IF: p = 0.003; PCR: p = 0.023) and activated microglia (IF: p<0.001; PCR: p = 0.009) was detected after ischemia. These levels were higher in the ranibizumab group (Iba1: IF: p<0.001; PCR: p = 0.018; CD68: IF: p<0.001; PCR: p = 0.004). Our findings demonstrate that photoreceptors and RGCs are protected by ranibizumab treatment. Only amacrine cells cannot be rescued. They seem to be particularly sensitive to ischemic damage and need maybe an earlier intervention.

Indexed as

Amacrine CellsAnimalsAqueous HumorCalcium-Binding ProteinsCell CountCholinergic NeuronsDisease Models, AnimalGlial Fibrillary Acidic ProteinHumansIschemiaMiceMicrofilament ProteinsMicrogliaPhotoreceptor Cells, VertebrateProtective AgentsProtein BindingAif1 protein, ratCalcium-Binding ProteinsGlial Fibrillary Acidic ProteinMicrofilament ProteinsProtective AgentsRanibizumabRhodopsinRNA, MessengerVascular Endothelial Growth Factor Avascular endothelial growth factor A, rat

Identifiers

PMID28800629
PMCPMC5553852
OpenAlexW2744515607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.